Faculty Opinions recommendation of Aspiration induced by remifentanil: a double-blind, randomized, crossover study in healthy volunteers.

2014 ◽  
Author(s):  
Suzanne Karan ◽  
Duncan McLean
Keyword(s):  
Crossover Study ◽  
Healthy Volunteers ◽  
Double Blind ◽  
Randomized Crossover Study

Citrate vs. acetate dialysate on intradialytic heparin dose: A double blind randomized crossover study

2016 ◽  
Vol 20 (4) ◽  
pp. 537-547 ◽  
Author(s):  
Kelvin C. W. Leung ◽  
Davina J. Tai ◽  
Pietro Ravani ◽  
Rob R. Quinn ◽  
Nairne Scott-Douglas ◽  
...  
Keyword(s):  
Crossover Study ◽  
Heparin Dose ◽  
Double Blind ◽  
Randomized Crossover Study

Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis

1991 ◽  
Vol 28 (3) ◽  
pp. 226-227 ◽  
Author(s):  
Gini F. Fleming ◽  
Everett E. Vokes ◽  
Jan-Marie McEvilly ◽  
Linda Janisch ◽  
Donna Francher ◽  
...  
Keyword(s):  
Crossover Study ◽  
Double Blind ◽  
Randomized Crossover Study

scholarly journals Pacemaker Current Inhibition in Experimental Human Cardiac Sympathetic Activation: A Double-Blind, Randomized, Crossover Study

2014 ◽  
Vol 95 (6) ◽  
pp. 601-607 ◽  
Author(s):  
C Schroeder ◽  
K Heusser ◽  
A A Zoerner ◽  
A Großhennig ◽  
D Wenzel ◽  
...  
Keyword(s):  
Crossover Study ◽  
Sympathetic Activation ◽  
Pacemaker Current ◽  
Double Blind ◽  
Randomized Crossover Study

An Evaluation of the Antihistamine Activity of Acrivastine and Its Onset in Human Skin

1992 ◽  
Vol 20 (2) ◽  
pp. 106-111 ◽  
Author(s):  
V K Manna ◽  
P Marks ◽  
J R Gibson
Keyword(s):  
Crossover Study ◽  
Healthy Volunteers ◽  
Human Skin ◽  
Treatment Plan ◽  
Onset Of Action ◽  
Double Blind ◽  
Time Points ◽  
Antihistamine Activity ◽  
Flare Response ◽  
Histamine Challenge

In a double-blind, two-period crossover study, 24 healthy volunteers were evaluated to establish the time of onset of action of activity of acrivastine in suppressing the weal and flare response to intradermally injected histamine. Volunteers received single doses of 8 mg acrivastine and placebo according to a fully randomized, balanced treatment plan. Acrivastine significantly ( P < 0.002) reduced the flare response induced by 0.4 μg histamine challenge 15 min after oral acrivastine dosing when compared with placebo. A significant ( P < 0.001) reduction of the weal response was noted at 25 min, although trends in this direction were already present at earlier time points. Dans d'une étude croisée à deux phase, réalisée en double aveugle et ayant porté sur 24 volontaires sains, on a tenté d'établir le moment du début de l'action de l'acrivastine dans la suppression de la réponse inflammatoire consécutive à l'injection intradermique d'histamine. Les volontaires ont reçu des doses uniques de 8 mg d'acrivastine et de placebo, selon un plan de traitement entièrement randomisé et équilibré. L'acrivastine a réduit significativement ( P < 0,002) la réponse de rubéfaction induite par 0,4 μg d'histamine 15 minutes après l'administration orale d'acrivastine, par rapport au placebo. Une réduction significative ( P < 0,001) de la réponse d'enflure a été notée à 25 minutes, bien qu'une tendance en ce sens ait déjà été observée à un stade plus précoce.

Pharmacokinetics and Safety of Coadministered Oseltamivir and Rimantadine in Healthy Volunteers: An Open-Label, Multiple-Dose, Randomized, Crossover Study

2012 ◽  
Vol 52 (8) ◽  
pp. 1255-1264 ◽  
Author(s):  
Georgina Cirrincione-Dall ◽  
Barbara J. Brennan ◽  
Rosa M. Ballester-Sanchis ◽  
Mercidita T. Navarro ◽  
Brian E. Davies
Keyword(s):  
Crossover Study ◽  
Healthy Volunteers ◽  
Multiple Dose ◽  
Open Label ◽  
Randomized Crossover Study
Sign in / Sign up

Export Citation Format

Share Document